Some people inherit a condition that makes their cholesterol extremely high from birth, leading to heart attacks at a very young age.
Claim Context
Familial hypercholesterolemia is associated with markedly elevated plasma cholesterol levels and premature coronary heart disease, with heterozygous individuals typically having cholesterol levels between 300–400 mg/dL and experiencing heart attacks between ages 35 and 60, while homozygous individuals may have levels near 800 mg/dL and suffer heart attacks as early as age 5.
“He delineated two clinically distinct forms of FH... the homozygous form, in which affected individuals manifest severe hypercholesterolemia at birth (with plasma cholesterol levels of about 800 mg/dl) and heart attacks that occur as early as 5 years of age, and the heterozygous form, characterized...”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Provide pooled estimates of cholesterol levels and cardiovascular risk in familial hypercholesterolemia across multiple registries.
A systematic review of 20 national FH registries, summarizing mean LDL, age of first cardiovascular event, and mortality rates in heterozygous and homozygous patients, with meta-analysis of untreated cohorts.
Track natural history of FH and predict outcomes based on genotype and baseline cholesterol.
A prospective cohort study following 5,000 genetically confirmed FH patients from age 10 onward, recording LDL levels, cardiovascular events, and survival, comparing homozygous vs heterozygous forms.
Illustrate clinical presentation and progression in rare homozygous cases.
A case series of 50 homozygous FH patients treated at specialized lipid clinics, documenting age of diagnosis, cholesterol levels, imaging findings, and response to therapy.
Estimate current burden of FH and associated cholesterol levels in a population.
A national screening program testing cholesterol in 100,000 adults aged 20+, identifying probable FH cases using Dutch Lipid Clinic criteria, and confirming with genetic testing in a subset.
Provide clinical context and management recommendations based on accumulated experience.
A consensus statement by lipid experts summarizing diagnostic criteria, risk stratification, and treatment approaches for familial hypercholesterolemia.